Targeting the gatekeeper residue in phosphoinositide 3-kinases

被引:54
作者
Alaimo, PJ
Knight, ZA
Shokat, KM [1 ]
机构
[1] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Program Chem & Chem Biol, San Francisco, CA 94143 USA
[3] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA
关键词
PI3-kinase; inhibition; gatekeeper;
D O I
10.1016/j.bmc.2005.02.021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A single residue in the ATP binding pocket of protein kinases-termed the gatekeeper-has been shown to control sensitivity to a wide range of small molecule inhibitors (Chem. Biol. 2004, 11, 691; Chem. Biol. 1999, 6, 671). Kinases that possess a small side chain at this position (Thr, Ala, or Gly) are readily targeted by structurally diverse classes of inhibitors, whereas kinases that possess a larger residue at this position are broadly resistant. Recently, lipid kinases of the phosphoinositide 3-kinase (PI3-K) family have become the focus of intense research interest as potential drug targets (Chem. Biol. 2003, 10, 207; Curr. Opin. Pharmacol. 2003, 3, 426). In this study, we identify the residue that corresponds structurally to the gatekeeper in PI3-Ks, and explore its importance in controlling enzyme activity and small molecule sensitivity. Isoleucine 848 of p110 alpha was mutated to alanine and glycine, but the mutated kinase was found to have severely impaired enzymatic activity. A structural bioinformatic comparison of this kinase with its yeast orthologs identified second site mutations that rescued the enzymatic activity of the 1848A kinase. To probe the dimensions of the gatekeeper pocket, a focused panel of analogs of the PI3-K inhibitor LY294002 was synthesized and its activity against gatekeeper mutated and wild-type p110 alpha was assessed. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2825 / 2836
页数:12
相关论文
共 40 条
[1]  
Aniol M, 1997, HETEROCYCLES, V45, P1069
[2]   A chemical switch for inhibitor-sensitive alleles of any protein kinase [J].
Bishop, AC ;
Ubersax, JA ;
Petsch, DT ;
Matheos, DP ;
Gray, NS ;
Blethrow, J ;
Shimizu, E ;
Tsien, JZ ;
Schultz, PG ;
Rose, MD ;
Wood, JL ;
Morgan, DO ;
Shokat, KM .
NATURE, 2000, 407 (6802) :395-401
[3]   Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors [J].
Blencke, S ;
Zech, B ;
Engkvist, O ;
Greff, Z ;
Örfi, L ;
Horváth, Z ;
Kéri, G ;
Ullrich, A ;
Daub, H .
CHEMISTRY & BIOLOGY, 2004, 11 (05) :691-701
[4]   Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors [J].
Blencke, S ;
Ullrich, A ;
Daub, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (17) :15435-15440
[5]   Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer [J].
Cappuzzo, F ;
Magrini, E ;
Ceresoli, GL ;
Bartolini, S ;
Rossi, E ;
Ludovini, V ;
Gregorc, V ;
Ligorio, C ;
Cancellieri, A ;
Damiani, S ;
Spreafico, A ;
Paties, CT ;
Lombardo, L ;
Calandri, C ;
Bellezza, G ;
Tonato, M ;
Crinò, L .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) :1133-1141
[6]   Alkylation of dianions derived from 2-(1-iminoalkyl) phenols: Synthesis of functionalized 2-acyl phenols. [J].
Cimarelli, C ;
Palmieri, G .
TETRAHEDRON, 1998, 54 (51) :15711-15720
[7]   Recovery from DNA replicational stress is the essential function of the S-phase checkpoint pathway [J].
Desany, BA ;
Alcasabas, AA ;
Bachant, JB ;
Elledge, SJ .
GENES & DEVELOPMENT, 1998, 12 (18) :2956-2970
[8]   Nickel catalysed electrosynthesis of ketones from organic halides and iron pentacarbonyl.: Part 2:: Unsymmetrical ketones [J].
Dolhem, E ;
Barhdadi, R ;
Folest, JC ;
Nédelec, JY ;
Troupel, M .
TETRAHEDRON, 2001, 57 (03) :525-529
[9]   Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].
Druker, BJ ;
Tamura, S ;
Buchdunger, E ;
Ohno, S ;
Segal, GM ;
Fanning, S ;
Zimmermann, J ;
Lydon, NB .
NATURE MEDICINE, 1996, 2 (05) :561-566
[10]   Molecularly targeted Therapy: Have the floodgates opened? [J].
Druker, BJ .
ONCOLOGIST, 2004, 9 (04) :357-360